Choi Soo Jeong, Kim Eun Jung, Park Moo Yong, Kim Jin Kuk, Hwang Seung Duk
Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon Hospital, Korea.
Perit Dial Int. 2014 Jun;34(4):376-82. doi: 10.3747/pdi.2011.00152. Epub 2013 Feb 1.
Peritoneal dialysis (PD) is characterized by a gain in fat mass. Unlike subcutaneous fat, visceral fat is associated with metabolic syndrome and survival. We prospectively examined whether visceral or subcutaneous fat could predict outcome in patients undergoing PD.
We studied 117 new patients (57 men) undergoing PD between February 2006 and November 2011. Baseline body composition was measured on computed tomograms. Visceral obesity was defined as a visceral fat area exceeding 100 cm(2), and subcutaneous obesity, as a subcutaneous fat area exceeding 130 cm(2).
Among the 117 patients, 37 and 29 were diagnosed with visceral and subcutaneous obesity respectively. Visceral and subcutaneous obesity were both present in 21 patients. In the study population, the 1-year and 5-year survival rates were 94% and 59%. The rates of peritonitis and exit-infection were 0.31 and 0.14 episodes per patient-year. Mortality was greater in patients with visceral obesity than in those without visceral obesity (p = 0.005). Visceral obesity had no influence on peritonitis and exit-infection rates. Subcutaneous obesity was associated neither with survival nor with peritonitis or exit-site infection. In a multivariate Cox regression analysis, visceral obesity was not a risk factor for poor outcome.
Increased visceral fat at PD initiation is not an independent predictor of poor survival. Any impact of visceral or subcutaneous fat mass on outcomes in patients undergoing PD would be better defined by larger, long-term studies.
腹膜透析(PD)的特点是脂肪量增加。与皮下脂肪不同,内脏脂肪与代谢综合征及生存率相关。我们前瞻性地研究了内脏脂肪或皮下脂肪是否能预测接受PD治疗患者的预后。
我们研究了2006年2月至2011年11月期间接受PD治疗的117例新患者(57例男性)。通过计算机断层扫描测量基线身体成分。内脏肥胖定义为内脏脂肪面积超过100 cm²,皮下肥胖定义为皮下脂肪面积超过130 cm²。
117例患者中,分别有37例和29例被诊断为内脏肥胖和皮下肥胖。21例患者同时存在内脏肥胖和皮下肥胖。在研究人群中,1年和5年生存率分别为94%和59%。腹膜炎和出口感染率分别为每位患者每年0.31次和0.14次。内脏肥胖患者的死亡率高于无内脏肥胖患者(p = 0.005)。内脏肥胖对腹膜炎和出口感染率无影响。皮下肥胖与生存率、腹膜炎或出口部位感染均无关联。在多变量Cox回归分析中,内脏肥胖不是预后不良的危险因素。
PD开始时内脏脂肪增加并非生存不良的独立预测因素。内脏或皮下脂肪量对接受PD治疗患者预后的任何影响,将通过更大规模的长期研究得到更好的界定。